3940 Trust Way
shRNA vs siRNA: Benitec's ddRNAi Explained
135 articles with Benitec Biopharma
Benitec Biopharma Limited announces it has entered into a securities purchase agreement with certain sophisticated and professional investors in the United States to issue 2,800,000 American Depositary Shares, with each ADS representing 20 fully paid ordinary shares, at a purchase price of US$0.70 per ADS, in a registered direct offering.
Benitec Biopharma Ltd (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D. Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the Ladenburg Thalmann 2019 Healthcare Conference
Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), today announced their plans to complete three non-clinical studies that will facilitate the filing of an Investigational New Drug (IND) application and the formal initiation of a Phase I clinical trial in patients suffering from Oculopharyngeal Muscular Dystrophy (OPMD).
Benitec Biopharma, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, announced its Appendix 4C for the quarter ending 31 July 2019.
Benitec Biopharma Limited announced the termination of the License and Collaboration Agreement with Axovant Sciences, as the Benitec team endeavors to conduct several additional exploratory analyses prior to the initiation of the clinical study in order to potentially improve the biological efficacy of the compound via further optimization of the proprietary delivery method employed to dose the target tissues.
Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) (the "Company"), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced that BB-401, a gene silencing agent comprised of plasmid DNA which produces a 39-nucleotide antisense RNA with specificity against EGFR, is currently undergoing evaluation in a Phase II clinical trial
Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
Benitec Biopharma Limited announced that it has licensed to Axovant Sciences ("Axovant") the exclusive global rights for BB-301
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec Biopharma.
Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update
Benitec Biopharma Limited reported its consolidated financial results for the 2018 fiscal third quarter to 31 March 2018.
Benitec Biopharma Limited announced that it will host a conference call and webcast for investors and analysts on 15 May 2018.
HNSCC and OPMD program update
Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
Benitec Biopharma Ltd today reported its consolidated financial results for the 2018 fiscal second quarter to 31 December 2017 (2Q FY18), and highlighted recent progress in advancing its pipeline.
Benitec Receives U.S. Orphan Drug Designation for BB-301, its ddRNAi Therapeutic for the Treatment of Oculopharyngeal Muscular Dystrophy
The Orphan Drug Designation granted to Benitec may provide a range of valuable benefits, including fast track process for clinical regulatory approval.
In addition, over the past several weeks, the Benitec team has now completed pre-IND and scientific advice meetings with the U.S. FDA, Health Canada and several European agencies.
Benitec is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued in the United States.
Benitec Release: Key Pre-Clinical Data On Oculopharyngeal Muscular Dystrophy (OPMD) Published In Nature Communications